Eye and Ciprofloxacin


Eye Symptoms and Causes

Your Eyes are an important part of your health. Most people rely on their Eyes to see and make sense of the world around them. But some Eye diseases can lead to vision loss, so it is important to identify and treat Eye diseases as early as possible. You should get your Eyes checked as often as your health care provider recommends it, or if you have any new vision problems. And just as it is important to keep your body healthy, you also need to keep your Eyes healthy.

Eye Care Tips

There are things you can do to help keep your Eyes healthy and make sure you are seeing your best:

  • Eat a healthy, balanced diet. Your diet should include plenty or fruits and vegetables, especially deep yellow and green leafy vegetables. Eating fish high in omega-3 fatty acids, such as salmon, tuna, and halibut can also help your Eyes.
  • Maintain a healthy weight. Being overweight or having obesity increases your risk of developing diabetes. Having diabetes puts you at higher risk of getting diabetic retinopathy or glaucoma.
  • Get regular exercise. Exercise may help to prevent or control diabetes, high blood pressure, and high cholesterol. These diseases can lead to some Eye or vision problems. So if you exercise regularly, you can lower your risk of getting these Eye and vision problems.
  • Wear sunglasses.Sun exposure can damage your Eyes and raise your risk of cataracts and age-related macular degeneration. Protect your Eyes by using sunglasses that block out 99 to 100 percent of both UV-A and UV-B radiation.
  • Wear protective Eye wear. To prevent Eye injuries, you need Eye protection when playing certain sports, working in jobs such as factory work and construction, and doing repairs or projects in your home.
  • Avoid smoking. Smoking increases the risk of developing age-related Eye diseases such as macular degeneration and cataracts and can damage the optic nerve.
  • Know your family health history. Some Eye diseases are inherited, so it is important to find out whether anyone in your family has had them. This can help you determine if you are at higher risk of developing an Eye disease.
  • Know your other risk factors. As you get older, you are at higher risk of developing age-related Eye diseases and conditions. It is important to know you risk factors because you may be able to lower your risk by changing some behaviors.
  • If you wear contacts, take steps to prevent Eye infections. Wash your hands well before you put in or take out your contact lenses. Also follow the instructions on how to properly clean them, and replace them when needed.
  • Give your Eyes a rest. If you spend a lot of time using a computer, you can forget to blink your Eyes and your Eyes can get tired. To reduce Eyestrain, try the 20-20-20 rule: Every 20 minutes, look away about 20 feet in front of you for 20 seconds.
Eye Tests and Exams

Everyone needs to have their Eyesight tested to check for vision and Eye problems. Children usually have vision screening in school or at their health care provider's office during a checkup. Adults may also get vision screenings during their checkups. But many adults need more than a vision screening. They need a comprehensive dilated Eye exam.

Getting comprehensive dilated Eye exams is especially important because some Eye diseases may not have warning signs. The exams are the only way to detect these diseases in their early stages, when they are easier to treat.

The exam includes several tests:

  • A visual field test to measure your side (peripheral) vision. A loss of peripheral vision may be a sign of glaucoma.
  • A visual acuity test, where you read an Eye chart about 20 feet away, to check on how well you see at various distances
  • Tonometry, which measures your Eye's interior pressure. It helps to detect glaucoma.
  • Dilation, which involves getting Eye drops that dilate (widen) your pupils. This allows more light to enter the Eye. Your Eye care provider examines your Eyes using a special magnifying lens. This provides a clear view of important tissues at the back of your Eye, including the retina, macula, and optic nerve.

If you have a refractive error and are going to need glasses or contacts, then you will also have a refraction test. When you have this test, you look through a device that has lenses of different strengths to help your Eye care professional figure out which lenses will give you the clearest vision.

At what age you should start getting these exams and how often you need them depends on many factors. They include your age, race, and overall health. For example, if you are African American, you are at higher risk of glaucoma and you need to start getting the exams earlier. If you have diabetes, you should get an exam every year. Check with your health care provider about if and when you need these exams.

Check out the latest treatments for eye

eye treatment research studies

Ciprofloxacin clinical trials, surveys and public health registries

Find Drug Side Effect reports

Ciprofloxacin Side Effects

Arthralgia (550)
Pain In Extremity (389)
Tendonitis (280)
Diarrhoea (274)
Pyrexia (260)
Renal Failure Acute (240)
Tendon Pain (237)
Dizziness (236)
Headache (234)
Anxiety (233)
Myalgia (229)
Nausea (225)
Pain (225)
Paraesthesia (219)
Insomnia (208)
Fatigue (204)
Rash (202)
Gait Disturbance (196)
Confusional State (187)
Tendon Rupture (174)
Asthenia (173)
Hypoaesthesia (168)
Pruritus (165)
Vomiting (163)
Dyspnoea (159)
Oedema Peripheral (147)
Muscular Weakness (140)
Muscle Spasms (132)
Abdominal Pain (129)
Neuropathy Peripheral (128)
Back Pain (127)
Burning Sensation (126)
International Normalised Ratio Increased (126)
Erythema (124)
Tendon Disorder (121)
Malaise (113)
Depression (112)
Feeling Abnormal (110)
Urticaria (109)
Musculoskeletal Pain (107)
Chest Pain (105)
Joint Swelling (104)
Convulsion (99)
Condition Aggravated (98)
Sepsis (94)
Agitation (94)
Tinnitus (93)
Abasia (93)
Palpitations (93)
Urinary Tract Infection (89)

➢ More

Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)

Eye Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Using in Vivo Confocal Microscopy to Assess Cellular Response and Efficacy of Steroid Treatment in Dry Eye Disease
Condition: Dry Eye Syndrome
Interventions: Drug: loteprednol etabonate (Lotemax);   Drug: Soothe Tired Eyes Lubricant Eye Drop
Outcome Measure: To evaluate the efficacy of Lotemax as compared to Soothe Tired Eyes Lubricant Eye Drop , using clinical and in vivo confocal microscopic findings.
2 Recruiting The Effect of "Eye Drop Guide" on the Success Rate of Eye Drops Self-instillation in Glaucoma Patients
Condition: Eye Drops Self-instillation
Interventions: Device: Eye Drop Guide technique;   Behavioral: Routine self-instillation technique
Outcome Measures: To compare the success rate of self-instillation eye drops between carefully instructed routine technique and the use of Eye Drop Guide.;   1. To compare the total number of drops dispensed and time to instill drop between 2 groups.;   2. To identify the factors that associated with failure of using the Eye Drop Guide.
3 Recruiting Study of Cyclosporine Ophthalmic Soution Group and Cyclosporine Ophthalmic Suspension Group
Condition: Dry Eye Syndromes
Intervention: Drug: Cyclosporine ophthalmic solution
Outcome Measures: Corneal staining test;   Ocular surface disease index (OSDI);   Tear break up time (TBUT);   Non-anesthetic Schirmer test;   Conjunctival staining
4 Recruiting Eye Rubbing and Transient Change in Corneal Parameters
Condition: Ectasia
Interventions: Other: Eye rubbing;   Other: No eye rubbing
Outcome Measures: changes in corneal parameters following eye rubbing;   Relationship between eyeball dimensions following eye rubbing
5 Recruiting RTA 408 Ophthalmic Suspension for the Treatment of Ocular Inflammation and Pain Following Ocular Surgery
Condition: Inflammation and Pain Following Ocular Surgery
Interventions: Drug: RTA 408 0.5% Ophthalmic Suspension;   Drug: RTA 408 1.0% Ophthalmic Suspension
Outcome Measures: Anterior Chamber Cell Count;   Pain
6 Recruiting Therapeutic Efficacy of APD-209 Eye Drops in Treatment of Epidemic Keratoconjunctivitis (EKC)
Condition: Viral Conjunctivitis
Interventions: Drug: APD-209 Eye drops;   Drug: APD-209 Placebo Eye drops
Outcome Measures: The primary objective is to assess the adenoviral load in epidemic keratokonjunctivitis (EKC) infected Eyes following topical treatment with APD-209 Eye drops compared to placebo.;   Assess the time to viral eradication in EKC infected Eyes following treatment with APD-209 Eye drops compared to placebo.;   Evaluate the effect of APD-209 Eye drops on clinical resolution of EKC, as measured by objective and subjective assessment of scaled clinical symptoms, compared to placebo.;   Evaluate the presence of opacities (quantitatively and qualitatively) following treatment with APD-209 Eye drops compared to placebo.;   Assess the visual acuity following treatment with APD-209 Eye drops compared to placebo.;   Assess the frequency of second eye infections.;   Assess the safety and tolerability of APD-209 Eye drops.
7 Recruiting The Utility of in Vivo Confocal Microscopy to Assess Cellular Response and Efficacy of Long-term Topical Steroid Treatment in Patients With Dry Eye Disease
Condition: Dry Eye Disease
Interventions: Drug: Lotemax;   Drug: Artificial Tears
Outcome Measures: In Vivo Confocal Microscopy (IVCM): Superficial corneal epithelial cells: Density, size, and hypereflectivity;   In Vivo Confocal Microscopy: Corneal subbasal immune dendritiform cells: Density, size, and cell field;   In Vivo Confocal Microscopy: Corneal subbasal nerves: Number and length of the main nerves and the branches;   Ocular Signs: Corneal epitheliopathy;   Ocular Signs: Conjunctival epitheliopathy;   Ocular Signs: Tear Break Up Time (TBUT);   Ocular Signs: Schirmer's Test with Anesthesia;   Ocular Signs: Intraocular pressure (IOP) by measure of applanation tonometry;   Ocular Symptoms: Ocular Surface Disease Index (OSDI) questionnaire;   Ocular Symptoms: • Symptom Assessment iN Dry Eye (SANDE) questionnaire
8 Recruiting Canadian Eye Injury Registry
Condition: Eye Injuries
Intervention: Behavioral: Public Health strategies
Outcome Measures: Number and type of eye injuries occurring in Canada;   Ocular Trauma Score
9 Unknown  Comparative Study of Thymosin Beta 4 Eye Drops vs. Vehicle in the Treatment of Severe Dry Eye
Conditions: Dry Eye;   Sjogren's Syndrome;   Graft vs. Host Disease
Intervention: Drug: Thymosin Beta 4 eye drops vs. vehicle
Outcome Measures: Corneal and Conjunctival Staining - Change from baseline;   Snellen visual acuity - Change from baseline
10 Recruiting Safety and Efficacy of rhNGF Eye Drops at Different Doses in Patients With Dry Eye
Condition: Dry Eye Syndrome.
Interventions: Biological: Human nerve growth factor 20 µg/mL;   Biological: Human nerve growth factor 4 µg/mL or 60 µg/mL
Outcome Measures: Symptom Assessment in Dry Eye (SANDE);   Ocular surface vital staining;   Schirmer test type I;   Treatment-emergent adverse events (TEAEs),;   Visual analogue scale (VAS);   Slit lamp examination;   Schirmer test type II (with anaesthesia);   Tear Film Break-Up Time (TFBUT);   Corneal fluorescein staining;   Corneal sensitivity (Cochet-Bonnet aesthesiometry);   Intraocular Pressure (IOP);   Ocular Surface Disease Index (OSDI);   Visual acuity;   Fundus ophthalmoscopy;   Tear Film osmolarity;   Conjunctival impression cytology for goblet cells' count Tear Film osmolarity;   Frequency of artificial tears use
11 Not yet recruiting A Phase 1/2 Multicenter, Randomized, Study to Evaluate the Safety and Efficacy of VS101 Subconjunctival Latanoprost Insert in Subjects With Open-Angle Glaucoma or Ocular Hypertension
Conditions: Open Angle Glaucoma;   Ocular Hypertension
Interventions: Drug: VS101 Insert Dose A;   Drug: VS101 Insert Dose B;   Drug: VS101 Insert Dose C;   Drug: Latanoprost 0.005% eye drops
Outcome Measure: Intra-ocular pressure
12 Recruiting Dry Eye Symptoms and Quality of Life
Condition: Dry Eyes
Intervention: Other: Dry Eyes
Outcome Measures: • Difference in SPEED Questionnaire and SANDE Questionnaire that affects patient health related quality of life (HRQOL);   • Difference in both (SPEED and SANDE) questionnaires and utility values that affects patient health related quality of life (HRQOL);   Production of Tear flow;   Tear break up time (TBUT);   Corneal flourescein staining
13 Recruiting Ocular Surface Immune Response in Dry Eye Disease: Analysis of Conjunctival and Peripheral Corneal Immune Cell Alterations by In Vivo Confocal Microscopy and Clinical Correlation
Condition: Dry Eye Disease
Intervention: Other: In vivo confocal microscopy (IVCM)
Outcome Measures: Peripheral Corneal Immune cell Status by IVCM;   Bulbar conjunctival immune cell Status by IVCM;   Clinical Parameter: Ocular Surface Disease Index (OSDI);   Clinical Parameter: Schirmer's II test;   Clinical Parameter: Conjunctival staining with lissamine green;   Clinical Parameter: Corneal staining with fluorescein;   Clinical Parameter: Tear Break Up Time (TBUT);   Clinical Parameter: Conjunctival redness
14 Unknown  The Effects of Preservative-free Prostaglandin Eye Drops in Sign and Symptoms on the Eyes of Patients With Glaucoma
Conditions: Ocular Hypertension;   Open-Angle Glaucoma
Intervention: Drug: Tafluprost 0.0015%
Outcome Measures: Change from screening in corneal confocal microscopic findings at month 12;   Change from screening in ocular symptoms and signs upon non-instillation
15 Recruiting Spectral Domain Optical Coherence Tomography Imaging of the Eyes of Neonates
Conditions: Retinal Diseases;   Optic Nerve Diseases
Interventions: Other: Observational: to better characterize the retina and optic nerve in newborns using spectral domain optical coherence tomography (s-oct).;   Procedure: OCT imaging.
Outcome Measure: Specific eye measurements by SD-OCT, including retinal nerve fiber layer thickness per quadrant, foveal depth, optic cup area and depth, optic nerve/foveal distance and depth of various layers within the retina to determine neonatal baseline values.
16 Recruiting Pilot Study to Evaluate SYL1001 Safety and Effect in Patients With Ocular Pain
Conditions: Ocular Pain;   Dry Eye Syndrome
Interventions: Drug: SYL1001;   Drug: Placebo
Outcome Measures: Changes from Baseline in the Ocular Pain Scores on the Visual Analog Scale (VAS) and in the Ocular Discomfort Scores on the Ocular Surface Disease Index (OSDI) as a Measure of SYL1001 Analgesic Effect versus Placebo.;   Simple Corneal and Conjunctival Evaluation as a Measure of Safety and Tolerability using Ophthalmic Dyes and a Slit Lamp;   Assessment of Adverse Events Appearance as a measure of SYL1001 tolerability;   Evaluation of Vital Signs, Blood, Urine and Ocular Parameters Alterations (IOP, Visual Acuity, Anterior Segment Exploration) Possibly Related to the Investigational Product
17 Recruiting Long-Term Safety of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
Conditions: Glaucoma;   Ocular Hypertension
Interventions: Drug: bimatoprost 0.01% ophthalmic solution;   Drug: bimatoprost 0.03% ophthalmic solution
Outcome Measures: Percentage of Patients Reporting One or More Treatment-Related Ocular Surface Adverse Events;   Percentage of Patients Reporting One or More Treatment-Related Ocular Surface Adverse Events excluding "Conjunctival Hyperemia"
18 Unknown  Ocular Rigidity and Outflow Facility in Glaucomatous and Normal Eyes
Condition: Glaucoma
Intervention: Procedure: Ocular rigidity, outflow facility and intraocular pressure measurement
Outcome Measures: Ocular rigidity coefficient;   Outflow facility coefficient;   Ocular pulse amplitude;   Pulsatile ocular blood flow
19 Recruiting Clinical Outcomes Following Treatment With Systane® Balance in Dry Eye Subjects
Condition: Dry Eye
Interventions: Drug: Propylene Glycol, 0.6% eye drops;   Drug: Preservative-free 0.9% Saline solution
Outcome Measures: Change from baseline in tear film break-up time (TFBUT) at Day 35;   Change from baseline in Total Ocular Surface Staining (TOSS) score at Day 35;   Change from baseline in ocular surface disease index (OSDI) score at Day 35;   Change from baseline in Impact of Dry Eye on Everyday Life (IDEEL) Treatment Effectiveness score at Day 35;   Change from baseline in IDEEL Treatment Inconvenience score at Day 35
20 Unknown  Treatment Study for Ischemic Optic Neuropathy With Opthalmic Timolol Maleate 0.5%
Conditions: Optic Neuropathy, Ischemic;   Anterior Ischemic Optic Neuropathy;   Ischemic Optic Neuropathy;   Optic Neuropathy, Anterior Ischemic
Intervention: Drug: Timolol maleate
Outcome Measures: Recruitment Rate of patients during the one year study to assess feasibility of a larger study;   Number of patients with adverse events;   Change in visual acuity at enrollment and three month follow up using a logMAR scale.;   Change in the mean deviation of actual versus predicted sensitivity of the visual field.;   Change in Colour vision as measured by HRR colour plates.;   Change in contrast sensitivity will be measured using the Pelli-Robson contrast sensitivity chart.